GeoVax Labs GOVX
- Market cap
- $1.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/a
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- $0
- −100% on a year ago
- Net margin
- n/a
- Free cash flow yield
- −1210.1%
Revenue was $0 over the last twelve months, down 100% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $300.7K | $2.8M | $864.4K | $1.6M | $852.3K+184% | $0 | $0 | $0 | $0 | |
| R&D | $6.9M+155% | $6.2M+66% | $4.4M+57% | $4.3M−9% | $7.4M+7% | $7.6M+22% | $5.4M+21% | $4.7M+11% | $5M−32% | $3M−61% | $3.9M−27% | $3.1M−34% |
| SG&A | $1.7M+32% | $1.5M−10% | $1.5M+0% | $1.1M−26% | $1.2M−25% | $1.6M+10% | $1.7M+16% | $1.5M+42% | $1.3M+7% | $1.4M−10% | $1.4M−19% | $1.3M−14% |
| −$8.6M+117% | −$7.7M+43% | −$5.9M+38% | −$5.1M−18% | −$5.9M−32% | −$8.3M+9% | −$5.4M−8% | −$5.4M+7% | −$6.4M+9% | −$4.4M−47% | −$5.3M−2% | −$4.4M−18% | |
| Interest expense | $0 | $0 | n/a | $7.3K | $14.1K | $0 | n/a | $0 | $0 | $0 | n/a | n/a |
| Net income | −$8.4M+112% | −$7.6M+41% | −$5.9M+45% | −$5.1M−15% | −$5.8M−31% | −$8.3M+9% | −$5.4M−8% | −$5.4M+6% | −$6.3M+9% | −$4.4M−47% | −$5.3M−2% | −$4.4M−18% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS, diluted: 10 periods, Q4 FY11 to Q4 FY21: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY11 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest GeoVax Labs' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GOVXGeoVax Labs | $1.5M | n/m | n/a | n/a | −100% | n/a | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| Peer median | $8.7M | 6.1× | 11.3× | 0.4× | −6% | 4.7% |
More on GeoVax Labs
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .